Diabetes Tech Society Gets FDA Buy-In For Glucose Monitor Surveillance Program
This article was originally published in The Pink Sheet Daily
Executive Summary
The proposed surveillance program would test marketed blood glucose monitor systems to ensure they are performing at the level expected when they were cleared. It was met with support from FDA, device companies, academics and patient advocates.
You may also be interested in...
Blood Glucose Meter Accuracy Problems Acknowledged By FDA, Industry And Clinicians
Certain 510(k)-cleared blood glucose meters do not perform at the regulatory standards for which they were cleared after they hit the market, stakeholders agree. FDA is working on the matter, but no clear plan of action was laid out at a Diabetes Technology Society meeting last week.
CDRH Focusing On New PMA Pathway, Clinical Trials Program In 2014/2015 Priorities
CDRH Director Jeffrey Shuren discussed the device center’s two-year strategic priorities with “The Gray Sheet.” The center plans to rebalance pre-market and post-market data collection, when appropriate, and improve the processes for starting up clinical trials in the U.S.
FDA Emphasizes “Deregulatory” Efforts In Mobile Medical Apps Final Guidance
In a long-awaited final guidance, FDA affirmed its plan to practice enforcement discretion for most mobile medical apps, except those applications that present the same risks as conventional FDA-regulated devices. Some digital health stakeholders praised the guidance, while others wished FDA had waited.